Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:IPCIF NASDAQ:LSTA NASDAQ:MTEX NASDAQ:SONN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIPCIFIntellipharmaceutics International$0.00$0.00▼$0.15$4.96M1.5312,042 shs793,500 shsLSTALisata Therapeutics$2.30+8.5%$2.52$1.87▼$4.20$20.15M1.0130,973 shs23,977 shsMTEXMannatech$8.27+2.7%$8.57$7.05▼$16.49$15.71M0.839,221 shs3,392 shsSONNSonnet BioTherapeutics$6.48+17.0%$4.15$1.08▼$19.30$44.24M1.211.61 million shs5.12 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIPCIFIntellipharmaceutics International0.00%0.00%0.00%0.00%0.00%LSTALisata Therapeutics-3.20%-2.75%-16.21%-11.67%-27.15%MTEXMannatech+0.86%-12.11%-9.51%-9.31%+8.07%SONNSonnet BioTherapeutics-6.10%+68.39%+56.50%+377.59%-14.56%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIPCIFIntellipharmaceutics International$0.00$0.00▼$0.15$4.96M1.5312,042 shs793,500 shsLSTALisata Therapeutics$2.30+8.5%$2.52$1.87▼$4.20$20.15M1.0130,973 shs23,977 shsMTEXMannatech$8.27+2.7%$8.57$7.05▼$16.49$15.71M0.839,221 shs3,392 shsSONNSonnet BioTherapeutics$6.48+17.0%$4.15$1.08▼$19.30$44.24M1.211.61 million shs5.12 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIPCIFIntellipharmaceutics International0.00%0.00%0.00%0.00%0.00%LSTALisata Therapeutics-3.20%-2.75%-16.21%-11.67%-27.15%MTEXMannatech+0.86%-12.11%-9.51%-9.31%+8.07%SONNSonnet BioTherapeutics-6.10%+68.39%+56.50%+377.59%-14.56%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIPCIFIntellipharmaceutics International 0.00N/AN/AN/ALSTALisata Therapeutics 3.00Buy$23.50921.74% UpsideMTEXMannatech 0.00N/AN/AN/ASONNSonnet BioTherapeutics 3.00Buy$20.00191.25% UpsideCurrent Analyst Ratings BreakdownLatest IPCIF, SONN, LSTA, and MTEX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/21/2025LSTALisata TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$15.007/15/2025LSTALisata TherapeuticsBrookline Capital ManagementSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$20.00 ➝ $32.00(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIPCIFIntellipharmaceutics International$660K0.00N/AN/A($0.32) per share0.00LSTALisata Therapeutics$1M20.15N/AN/A$3.49 per share0.66MTEXMannatech$112.98M0.14$2.26 per share3.65$4.57 per share1.81SONNSonnet BioTherapeutics$1M46.88N/AN/A($0.71) per share-9.67Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIPCIFIntellipharmaceutics International-$2.89M-$0.16N/AN/AN/AN/AN/AN/AN/ALSTALisata Therapeutics-$19.99M-$2.23N/AN/AN/AN/A-69.68%-59.44%11/11/2025 (Estimated)MTEXMannatech$2.49M-$2.04N/A∞N/A-3.46%-48.60%-10.70%11/10/2025 (Estimated)SONNSonnet BioTherapeutics-$7.44MN/A0.00∞N/AN/A-4,646.10%-342.21%N/ALatest IPCIF, SONN, LSTA, and MTEX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q3 2025SONNSonnet BioTherapeutics-$0.49-$0.95-$0.46-$0.95N/AN/A8/12/2025Q2 2025MTEXMannatechN/A-$2.27N/A-$2.27N/A$25.68 million8/7/2025Q2 2025LSTALisata Therapeutics-$0.65-$0.54+$0.11-$0.54N/A$0.07 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIPCIFIntellipharmaceutics InternationalN/AN/AN/AN/AN/ALSTALisata TherapeuticsN/AN/AN/AN/AN/AMTEXMannatech$0.202.42%N/AN/A N/ASONNSonnet BioTherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIPCIFIntellipharmaceutics InternationalN/AN/AN/ALSTALisata TherapeuticsN/A5.775.77MTEXMannatech0.581.110.49SONNSonnet BioTherapeuticsN/A0.260.26Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIPCIFIntellipharmaceutics InternationalN/ALSTALisata Therapeutics8.94%MTEXMannatech12.98%SONNSonnet BioTherapeutics9.45%Insider OwnershipCompanyInsider OwnershipIPCIFIntellipharmaceutics International1.76%LSTALisata Therapeutics9.10%MTEXMannatech41.50%SONNSonnet BioTherapeutics8.48%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIPCIFIntellipharmaceutics International1033.09 million32.51 millionNot OptionableLSTALisata Therapeutics308.76 million7.96 millionNot OptionableMTEXMannatech2501.90 million1.11 millionNot OptionableSONNSonnet BioTherapeutics106.83 million6.25 millionNot OptionableIPCIF, SONN, LSTA, and MTEX HeadlinesRecent News About These CompaniesBiotechs Turn to Digital Coins, Crypto to Boost Stock PricesAugust 25, 2025 | msn.comSonnet Biotherapeutics Faces Earnings Volatility with New HYPE Treasury Strategy and Accounting StandardsAugust 15, 2025 | msn.comSonnet Releases Virtual Investor "What This Means" SegmentAugust 11, 2025 | globenewswire.comThis Cancer Biotech Company Is Making a Big Bet on the HYPE Crypto. Should You Buy Its Stock Here?August 6, 2025 | msn.comSonnet BioTherapeutics Expands Clinical Evaluation of SON-1010 Dose Escalation with Atezolizumab in Ovarian CancerAugust 4, 2025 | globenewswire.comBeyond BTC and ETH: The Companies Turning to Alternative Crypto Treasury AssetsAugust 2, 2025 | msn.comSonnet BioTherapeutics Appoints Interim CEO Raghu RaoAugust 1, 2025 | tipranks.comSolana-based treasury model goes global as DeFi Development launches franchiseJuly 17, 2025 | msn.comWLFI tokens to become tradable after World Liberty holders’ voteJuly 17, 2025 | msn.comHyperliquid Strategies Inc. plan for $583M treasury boosts HYPE priceJuly 16, 2025 | cointelegraph.comSonnet BioTherapeutics Merges in $888M Deal to Launch Hyperliquid Strategies and HYPE TreasuryJuly 15, 2025 | thecurrencyanalytics.comTSonnet BioTherapeutics Stock Jumps 82% After Deal With Rorschach I: Retail Stays ExuberantJuly 15, 2025 | msn.comPublic Firm Sonnet BioTherapeutics to Launch HyperLiquid Treasury in New DealJuly 14, 2025 | coinspeaker.comSonnet BioTherapeutics Shares Climb After Plan to Transfer Into Public Crypto Treasury Co.July 14, 2025 | marketwatch.comWhy did Sonnet BioTherapeutics (SONN) Shares Gain over 200% in Premarket Trading?July 14, 2025 | tokenist.comTHyperliquid Price Forecast: HYPE eyes gains following Sonnet BioTherapeutics' rebrandJuly 14, 2025 | fxstreet.comHYPE coin price up 200%, Sonnet BioTherapeutics merges into Hyperliquid StrategiesJuly 14, 2025 | msn.comMassive deal sends biotech stock rallying 367%July 14, 2025 | msn.com$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Sonnet BioTherapeutics, Inc. (NASDAQ: SONN)July 14, 2025 | globenewswire.comWhy Is Sonnet BioTherapeutics Stock Trading Higher On Monday?July 14, 2025 | benzinga.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIPCIF, SONN, LSTA, and MTEX Company DescriptionsIntellipharmaceutics International OTCMKTS:IPCIFIntellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy; Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression; and Protonix, a pantoprazole sodium delayed-release tablet to treat gastroesophageal reflux disease. In addition, it provides Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes; Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Pristiq, a desvenlafaxine extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; and Ranexa, a ranolazine extended release tablet for chronic angina. Further, the company is developing OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Regabatin XR, a pregabalin extended-release capsule for the management of neuropathic pain. It has a license and commercialization agreement with Par Pharmaceutical Inc. Intellipharmaceutics International Inc. was founded in 1998 and is based in Toronto, Canada.Lisata Therapeutics NASDAQ:LSTA$2.30 +0.18 (+8.49%) Closing price 04:00 PM EasternExtended Trading$2.28 -0.01 (-0.65%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.Mannatech NASDAQ:MTEX$8.26 +0.22 (+2.67%) Closing price 03:57 PM EasternExtended Trading$8.26 0.00 (0.00%) As of 04:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mannatech, Incorporated operates as a health and wellness company in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific. The company develops, markets, and sells nutritional supplements; topical and skin care, and anti-aging products; and weight-management and fitness products. It primarily sells its products directly, as well as through e-commerce and network marketing channels. Mannatech, Incorporated was incorporated in 1993 and is headquartered in Flower Mound, Texas.Sonnet BioTherapeutics NASDAQ:SONN$6.48 +0.94 (+16.97%) Closing price 04:00 PM EasternExtended Trading$6.76 +0.28 (+4.32%) As of 04:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 that is in Phase 1b/2a clinical trial for the treatment of solid tumor indications, including ovarian cancer, non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6, which is in Phase 1b/I2a clinical trail to treat chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy; and SON-1210, a bispecific compound for solid tumor indications, including colorectal cancer. It has a license agreement with New Life Therapeutics Pte, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6; and strategic development collaboration with Sarcoma Oncology Center to advance SON-1210. The company is headquartered in Princeton, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Resideo Technologies: Institutional Activity Signals 30% Upside Lululemon’s Sell-Off Looks Overdone: A Contrarian Case Palantir’s Commercial Growth Story Is Just Getting Started How Bath & Body Works Is a Perfect Example of a Value Stock The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Uranium Energy Stock Has Momentum—and More Upside Ahead Why Opendoor Stock Is Soaring—and May Just Be Starting Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
